v3.25.2
Summary of Significant Accounting Policies (Tables)
 6 Months Ended
Jun. 30, 2025
Accounting Policies [Abstract]  
Schedule of Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share

The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would be anti-dilutive:

   2025   2024 
   As of June 30, 
   2025   2024 
Warrants [1]   3,849,308    689,293 
Options   9,460    9,671 
Series A Convertible Preferred Stock   72    72 
Series B Convertible Preferred Stock   2,067    2,067 
Total potentially dilutive shares   3,860,907    701,103 

 

[1] As part of the InflamaCORE, LLC license agreement, warrants to purchase 342 shares of common stock are to be issued upon the satisfaction of certain milestones and, accordingly, are not included in the amount currently reported.